Ozempic, Wegovy & Semaglutide vs Mounjaro: The Complete Guide
Confused between Ozempic, Wegovy, semaglutide, and Mounjaro? Here is the science, clearly laid out — which one activates which receptor, what the trials show for weight loss, and how it looks in Israel.
What is the difference between semaglutide and tirzepatide?
Ozempic and Wegovy are brand names for the same active ingredient — semaglutide — a single GLP-1 receptor agonist (Ozempic is approved for diabetes, Wegovy for obesity). Mounjaro contains tirzepatide, a dual agonist that activates both GLP-1 and GIP. In trials, tirzepatide showed a higher average weight loss (~21%) versus semaglutide (~15%), but both are prescription drugs that require medical supervision.
Ozempic, Wegovy & semaglutide — same compound, different names
One of the most common points of confusion: Ozempic and Wegovy are not two different compounds. Both contain the same active ingredient — semaglutide. The difference is in the approved indication and the doses: Ozempic was approved to treat type 2 diabetes, and Wegovy was approved specifically for weight management in obesity.
Semaglutide is a GLP-1 receptor agonist — it mimics a natural gut hormone that reduces appetite, slows gastric emptying, and improves insulin secretion.
Tirzepatide (Mounjaro) — the dual mechanism
Tirzepatide is fundamentally different: it is a dual agonist that simultaneously activates two receptors — GLP-1 and GIP. The added GIP activity may improve insulin sensitivity and how the body handles fat.
This dual mechanism is why tirzepatide produced a higher average weight loss in trials compared with semaglutide.
What the trials showed — efficacy comparison
- Semaglutide (Wegovy) in the STEP-1 trial: an average ~14.9% weight loss over 68 weeks.
- Tirzepatide (Mounjaro) in the SURMOUNT-1 trial: an average loss of up to ~20.9% over 72 weeks.
- In the head-to-head SURPASS-2 trial (in diabetes patients), tirzepatide outperformed semaglutide on weight loss and blood-sugar control.
- Both drugs improved accompanying cardio-metabolic measures.
Status in Israel
Ozempic and Mounjaro are registered in Israel to treat type 2 diabetes; Wegovy is marketed for weight management. All of these drugs require a doctor's prescription and are not available as a free supplement.
Health-basket inclusion criteria, indications, and reimbursement change from time to time. Verify the current status with your treating physician and HMO.
Safety and grey-market warning
The common side effects for both families are gastrointestinal — nausea, diarrhea, constipation, and vomiting, mainly at the start of treatment. There are rarer warnings (pancreatitis, a thyroid warning based on animal models).
"Grey market" products and "research-only" semaglutide/tirzepatide powders carry risks of purity, contamination, and incorrect dosing. The trial data do not apply to them. PepVero does not sell or supply any compounds.
Average weight loss: tirzepatide (SURMOUNT-1) versus semaglutide (STEP-1) in separate trials.
Frequently asked questions
Are Ozempic and Wegovy the same thing?
Both contain the same active ingredient — semaglutide. Ozempic was approved for type 2 diabetes, and Wegovy for weight management in obesity. The difference is in the indication and doses, not the compound.
Which is more effective — Mounjaro or Ozempic?
In trials, tirzepatide (Mounjaro) showed a higher average weight loss than semaglutide (Ozempic/Wegovy). However, the medical choice depends on the specific patient and the physician's judgment.
What is GLP-1 and what is GIP?
Both are gut hormones. GLP-1 reduces appetite and improves insulin secretion. GIP improves insulin sensitivity. Semaglutide activates only GLP-1; tirzepatide activates both.
Are these drugs approved in Israel?
Ozempic and Mounjaro are registered for type 2 diabetes and Wegovy for weight management. All require a prescription. Indications and reimbursement may change — verify with your physician and HMO.
Can you buy semaglutide or tirzepatide online?
Do not purchase from unregulated sources. Grey-market products carry risks of purity, contamination, and incorrect dosing, and the trial safety data do not apply to them. A prescription and medical supervision are required.
Sources
This page is for educational and research information only and is not medical advice, diagnosis, or a recommendation to obtain or use any compound. Semaglutide and tirzepatide are prescription drugs that require medical supervision. Do not obtain or use unregulated peptides. Consult a qualified physician.
Go deeper into the data
Compare metabolic peptides side by side, check the regulatory status in Israel, and read the evidence-scoring methodology.